Mediators of Inflammation / 2024 / Article / Tab 1 / Research Article
Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition Table 1 Association of NLRP3 levels with clinicopathological features from 62 bladder cancer patients.
Variables N Strong expressionn (%) Moderate expressionn (%) Weak/negative expressionn (%) P -valueSex Male 45 12 (26.67) 15 (33.33) 18 (40.00) 0.753 Female 17 5 (29.41) 4 (23.53) 8 (47.06) — Age (years) <68 31 9 (29.04) 11 (35.48) 11 (35.48) 0.563 ≥68 31 8 (25.81) 8 (25.81) 15 (48.38) — Tumorigenesis frequency Primary 44 10 (22.73) 13 (29.54) 21 (47.73) 0.288 Recurrence 18 7 (38.89) 6 (33.33) 5 (27.78) — Tumor number Unicity 28 7 (25.00) 10 (35.71) 11 (39.29) 0.733 Multiplicity 34 10 (29.41) 9 (26.47) 15 (44.12) — Tumor diameter ≤2 cm 33 5 (15.15) 10 (30.30) 18 (54.55) 0.038 >2 cm 29 12 (41.38) 9 (31.03) 8 (27.59) — Invasive type NMIBC 38 6 (15.79) 14 (36.84) 18 (47.37) 0.034 MIBC 24 11 (45.84) 5 (20.83) 8 (33.33) — Metastasis Yes 17 9 (52.94) 5 (29.41) 3 (17.65) 0.012 No 45 8 (17.78) 14 (31.11) 23 (51.11) — Histological grade High 36 11 (30.56) 10 (27.78) 15 (41.66) 0.764 Low 26 6 (23.08) 9 (34.61) 11 (42.31) — Smoking Yes 27 7 (25.93) 8 (29.63) 12 (44.44) 0.939 No 35 10 (28.57) 11 (31.43) 14 (40.00) — Drinking Yes 25 4 (16.00) 8 (32.00) 13 (52.00) 0.220 No 37 13 (35.14) 11 (29.72) 13 (35.14) — Hypertension Yes 33 11 (33.33) 10 (30.30) 12 (36.37) 0.490 No 29 6 (20.69) 9 (31.03) 14 (48.28) — Diabetes Yes 15 6 (40.00) 5 (33.33) 4 (26.67) 0.318 No 47 11 (23.40) 14 (29.79) 22 (46.81) — Body mass index (kg/m2 ) <24 31 8 (25.80) 10 (32.26) 13 (41.94) 0.946 ≥24 31 9 (29.03) 9 (29.03) 13 (41.94) —
NMIBC, nonmuscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.